Especially, as the SARS-CoV and SARS-CoV-2 shared the functional host receptor, angiotensin-converting enzyme 2 (ACE2), antiviral drugs/antibodies for SARS could be feasible candidates in the developing of radiolabeled theranostic treatment for COVID-19 [119]. This evidence concerns the gene ACE2 and severe acute respiratory syndrome.